Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Signs Of Change? Lilly, Merck, Janssen Report Slowing List Price Growth In 2018

Mon, 03/25/2019 - 2:24pm

Annual transparency reports from the three firms show US price increases continued, though less aggressively, and net prices declined for...

      Related Stories 

Novartis’ Srinivasan On Putting Data Analytics To Use In Clinical Development

Mon, 03/25/2019 - 6:32am

Badhri Srinivasan, head of global development operations at Novartis, outlines in an interview with Scrip the company’s efforts towards making clinical...

      Related Stories 

Pipeline Watch: Phase III Readouts For Vibegron, Doria And Ameluz

Mon, 03/25/2019 - 5:13am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Good DREAMM-1 Data Keeps GSK On Track For Multiple Myeloma Filing This Year

Sun, 03/24/2019 - 11:29pm

Confirmation of good trial data for GSK's promising anti-BCMA antibody-drug conjugate GSK2857916 in multiple myeloma patients keeps it in the running...

      Related Stories 

Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer

Fri, 03/22/2019 - 1:27pm

Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.

      Related Stories 

Obituary: James Diamond, Former ABPI President

Fri, 03/22/2019 - 6:51am

A highly respected industry leader, James Diamond served on the board of Beecham Group and was elected president of the...

      Related Stories 

Shionogi Stays The Course As It Lays Out R&D Priorities

Thu, 03/21/2019 - 11:39pm

Japan's Shionogi lays out its R&D priorities, with a continued strategic focus on anti-infectives and CNS drugs, saying it is...

      Related Stories 

Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis

Thu, 03/21/2019 - 5:59pm

Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen...

      Related Stories 

Conatus Endures Another NASH Setback With Failure To Hit Fibrosis Endpoint

Thu, 03/21/2019 - 2:08pm

The pan-caspase inhibitor emricasan, partnered with Novartis, misses fibrosis-reduction endpoint in Phase IIb study, following the failure last December of...

      Related Stories 

INFOGRAPHIC: NASH Pipeline: Racing To The Finish

Thu, 03/21/2019 - 11:23am

INFOGRAPHIC: As industry closes in on the first approved drug therapy for non-alcoholic steatohepatitis, our infographic details the dozens of...

      Related Stories 

Scandinavia Serves Up Two Partners For Alexion, In Its Rare Disease Sweet-Spot

Thu, 03/21/2019 - 9:02am

Leading US biotech Alexion is to collaborate with two European biotechs, Affibody and Zealand, on early-stage products for rare diseases...

      Related Stories 

What Brexit Effect? UK Biotech Start-Ups Reach Record Numbers

Thu, 03/21/2019 - 8:46am

With UK biotech venture capital investment at its highest level to date, biotech company building is showing no let up...

      Related Stories